New
HealthMore in Health→
Liver drug UDCA joins major Parkinson’s trial
Key Takeaways
- UDCA has joined the EJS ACT-PD Parkinson’s platform trial as its third active treatment arm.
- Researchers are testing whether the liver drug can improve mitochondrial function and slow disease progression.
- Earlier-stage testing found UDCA safe and well tolerated in people with Parkinson’s disease.
DE
DT Editorial Team··via medicalxpress.com